Kiniksa Pharmaceuticals International, Plc · NASDAQ:KNSA
Kiniksa Pharmaceuticals International — Q3 2022 Earnings Presentation
18 slides from Kiniksa Pharmaceuticals International's earnings presentation, Nov 1, 2022
Slide 1: Third Quarter 2022 Financial Results and Corporate Update
Third Quarter 2022 Financial Results and Corporate Update NOVEMBER 1, 2022
Slide 2: Agenda
Agenda Introduction | Sanj K. Patel, Chief Executive Officer Clinical Update| John F. Paolini, Chief Medical Officer ARCALYST® Commercial Execution | Ross Moat, Chief Commercial Officer Third Quarter 2022 Financial Results | Mark Ragosa, Chief Financial Officer Closing Remarks | Sanj K. Patel, Chief
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and i
Slide 4: Introduction
Introduction Sanj K. Patel Chief Executive Officer
Slide 5: Portfolio of Immune-Modulating Assets
Portfolio of Immune-Modulating Assets P R O G R AM & T AR G E T P R E C L I N IC AL P H AS E 1 P H AS E 2 P H AS E 3 C O M M E R CI AL KINIKSA RIGHTS R EC U R R EN T PER IC AR D ITIS ARCALYST® Worldwide5 C R YO PYR IN - ASSO C IAT ED PER IO D IC SYN D R O MES ( C APS) (rilonacept)1,2 (Excluding MENA
Slide 6: Clinical Update
Clinical Update John F. Paolini Chief Medical Officer
Slide 7: RHAPSODY Design
RHAPSODY Design Event-Driven Pivotal Study Long-Term Extension (LTE) (up to 24 months) Median rilonacept treatment duration prior to the LTE (RI+RW) was 9 months (range, 3-14) End of Treatment Primary Efficacy Endpoint 18 months after the most End of Study Loading Dose Randomization Time-to-First-Ad
Slide 8: RHAPSODY Long-Term Extension Data Demonstrated Continued Treatment Response Beyond 18 months
RHAPSODY Long-Term Extension Data Demonstrated Rilonacept Treatment Beyond 18 months Resulted in Continued Treatment Response1,2 Excerpted from Imazio M, Klein AL, et al. Prolonged Rilonacept Treatment in Rhapsody Long-term Extension Provided Persistent Reduction of Pericarditis Recurrence Risk. Cir
Slide 9: KPL-404 Phase 2 Trial in Rheumatoid Arthritis
KPL-404 Phase 2 Trial in Rheumatoid Arthritis Designed to provide PK data and early signal of efficacy with chronic (12-week) administration and optionality to evaluate KPL-404 across a range of other autoimmune diseases PHARMACOKINETICS (PK) LEAD-IN PROOF-OF-CONCEPT Amended Cohort 3 PATIENT POPULAT
Slide 10: ARCALYST Commercial Execution
ARCALYST Commercial Execution Ross Moat Chief Commercial Officer
Slide 11: Continued Execution Resulting in Steady ARCALYST Growth in Q3 2022
Continued Execution Resulting in Steady ARCALYST Growth in Q3 2022; On-Track for Annual Guidance of $115-130M Net Revenue Net Revenue $33.4 million in net • ARCALYST net revenue for Q3 2022 was $33.4 million revenue for the third • Represents ~24%, or $6.4M growth versus Q2 2022 quarter of 2022 • Co
Slide 12: Drivers of Continued ARCALYST Growth in Recurrent Pericarditis
Drivers of Continued ARCALYST Growth in Recurrent Pericarditis Total and Repeat Prescriber Growth per Quarter Physician Growth >650 • Steady growth of prescriber base with greater than 650 HCPs having prescribed ARCALYST since launch • Growing repeat prescriber base with 22% having prescribed ARCALY
Slide 13: Considerations for the Duration of ARCALYST Treatment
Considerations for the Duration of ARCALYST Treatment RECURRENT PERICARDITIS THOUGHT LEADER MOST PATIENTS WITH MULTIPLE RECURRENCES SUFFER POSITIONING OF ARCALYST IN TREATMENT ALGORITHM 1 FOR AT LEAST 2 YEARS 2 • ARCALYST treatment requires a change in mindset and practice for healthcare professiona
Slide 14: Strong Foundation for Growth by Supporting Hundreds of Recurrent Pericarditis Patients
Strong Foundation for Growth by Supporting Hundreds of Recurrent Pericarditis Patients ✓ Growing uptake amongst physicians continues to increase both breadth and depth of prescribing ✓ Patients are reporting very high satisfaction on ARCALYST treatment ✓ Solid commercial launch laying a strong found
Slide 15: Third Quarter 2022 Financials
Third Quarter 2022 Financials Mark Ragosa Chief Financial Officer
Slide 16: Third Quarter 2022 Financial Results
Third Quarter 2022 Financial Results Income Statement Q3 2022 Q3 2021 Product Revenue $33.4M $12.1M License and Collaboration Revenue $65.7M $0.0M Total Revenue $99.1M $12.1M Cost of Goods Sold $6.9M $2.8M Collaboration Expenses $4.6M $0.0M Research and Development $16.5M $19.2M Selling, General and
Slide 17: Closing Remarks
Closing Remarks Sanj K. Patel Chief Executive Officer
Slide 18: Third Quarter 2022 Financial Results and Corporate Update
Third Quarter 2022 Financial Results and Corporate Update NOVEMBER 1, 2022
Kiniksa Pharmaceuticals — Q3 2022 Earnings Presentation on 6ix